Heyman Richard A. (CIK 1584759) reported 14 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-07-28). Recent activity: Buy ORIC (3,500 shares), Sell ORIC (7,000 shares), Sell ORIC (6,100 shares), Sell ORIC (300 shares), Sell ELVN (1,230 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-28 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Buy | 3,500 | $5,600 |
| 2026-07-28 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Sell | 7,000 | $84,140 |
| 2026-07-28 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Sell | 6,100 | $73,322 |
| 2026-07-08 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Sell | 300 | $3,600 |
| 2026-02-19 | Enliven Therapeutics, Inc. (ELVN) | Director | Sell | 1,230 | $32,201 |
| 2026-01-22 | Enliven Therapeutics, Inc. (ELVN) | Director | Sell | 512 | $13,548 |
| 2026-01-22 | Enliven Therapeutics, Inc. (ELVN) | Director | Sell | 718 | $19,357 |
| 2026-01-20 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Sell | 3,500 | $42,000 |
| 2026-01-20 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Sell | 3,200 | $38,400 |
| 2026-01-12 | Enliven Therapeutics, Inc. (ELVN) | Director | Sell | 1,620 | $40,500 |
| 2026-01-12 | Enliven Therapeutics, Inc. (ELVN) | Director | Sell | 8,015 | $200,696 |
| 2026-01-12 | Enliven Therapeutics, Inc. (ELVN) | Director | Sell | 4,285 | $107,125 |
| 2025-10-03 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Buy | 31,353 | $50,165 |
| 2025-10-03 | Oric Pharmaceuticals, Inc. (ORIC) | Director | Buy | 1,447 | $5,426 |
Source: SEC Form 4 filings · as of 2026-07-28